

<b>Clinical characteristics</b>	<b>All patients (n=70)</b>	<b>POLARx (n=20)</b>	<b>Arctic Front PRO (n=50)</b>	<b>p-value</b>
Male Gender	54 (77.1)	12 (60)	42 (84)	0.056
Age	62.5 (55-69)	63 (59.6)	61 (53-70.2)	0.984
Paroxysmal	66 (94.3)	19 (95)	47 (94)	1.00
Hypertension	27 (38.6)	12 (60)	15 (30)	0.03
Diabetes	4 (5.7)	1 (5)	3 (6)	1.00
Previous stroke/TIA	5 (7.1)	1 (5)	4 (8)	1.00
CKD	1 (1.4)	0 (0)	1 (2)	1.00
Smoker	12 (17.1)	2 (10)	10 (20)	0.487
CAD	10 (14.3)	1 (5)	9 (18)	0.262
CHA <sub>2</sub> DS <sub>2</sub> -VASc	1 (0-2.25)	1.5 (0-2.0)	1.0 (0-3.0)	0.606
Betablocker	28 (40)	10 (50)	18 (36)	0.295
Calcium antagonist	9 (12.9)	2 (10)	7 (14)	1.00
ACE-inhibitor	28 (40)	10 (50)	18 (36)	0.295
Antiagregation	6 (8.6)	2 (10)	4 (8)	1.00
Anti-arrhythmic drugs				0.228
Sodium blockers	34 (48.5)	10 (50)	23 (46)	
Sotalol	2 (2.8)	2 (1)	0 (0)	
Amiodarone	14 (20)	3 (15)	11 (22)	
Anticoagulants				0.816
DOAC	45 (64.3)	13 (65)	32 (64)	
VKA	1 (1.4)	0 (0)	1 (2)	
LA size (ml/m <sup>2</sup> )	34 (31-42)	36 (30-41)	33 (31-43)	0.970
LVEF (%)	62 (57-67)	60 (57-66)	62 (56.7-67)	0.412

**Table 1. Baseline clinical characteristics**

\* Variables are presented as number (%) or median (Q1-Q3).

**TIA:** transient ischemic attack; **CKD:** chronic kidney disease; **CAD:** coronary artery disease; **ACE:** angiotensin-converting enzyme; **DOAC:** direct oral anticoagulants; **VKA:** vitamin K antagonist; **LA:** left atrium; **LVEF:** left ventricular ejection fraction.